# Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)

> **NCT04858529** · PHASE3 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 774 (estimated)

## Conditions studied

- Neoadjuvant Therapies for HER2+ Breast Cancer

## Interventions

- **DRUG:** investigator-selected taxane/carboplatin/trastuzumab/pertuzumab (TCHP)
- **DRUG:** investigator-selected taxane/trastuzumab/pertuzumab (THP)

## Key facts

- **NCT ID:** NCT04858529
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-30
- **Primary completion:** 2024-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 774 (ESTIMATED)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858529, "Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04858529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*